Rs 50 Crore Boost for Drug Discovery in India: Startups Get Pharma Scheme Support

The government is offering startups up to Rs 50 crore for new drug discovery under a dedicated pharma incentive scheme, in a decisive push to move drug discovery in India beyond generics. The programme aims to nurture home-grown drug discovery in India by funding early-stage research that private investors often consider too risky. Industry leaders have welcomed the announcement but cautioned that money alone will not deliver breakthroughs, they want faster regulatory pathways to match the financial backing.

What the Scheme Offers Drug Discovery in India

Under the pharma incentive scheme, eligible startups can access grants of up to Rs 50 crore for new drug discovery projects spanning target identification to pre-clinical development. Officials said the pharma incentive scheme prioritises novel candidates over incremental reformulations, signalling that the era of rewarding only me-too drugs is ending. The funding is expected to de-risk the earliest, most failure-prone stages of pharmaceutical research funding, where Indian startups currently struggle to raise capital. For Indian drug startups working on unproven biology, the funding could be the difference between shelving an idea and testing it. Officials said applications will be evaluated by an expert committee with representation from industry, academia and drug regulators, and the first funding calls are expected within months.

Why Drug Discovery in India Needs a Push

India is rightly called the pharmacy of the world, but the title rests on affordable generics, not original molecules. Decades of process-chemistry excellence built manufacturing scale, yet drug discovery in India has lagged for familiar reasons: high failure rates, long gestation and scarce risk capital. Public pharmaceutical research funding has traditionally favoured established institutions over nimble startups. The programme's stated goal is genuine innovation, not incremental tweaks, and officials acknowledge that drug discovery in India will not scale on manufacturing strength alone, it needs dedicated risk capital and a startup-friendly ecosystem. Countries such as South Korea and Singapore showed that sustained public investment in early research can build world-class discovery ecosystems within two decades.

Industry Reaction: What Drug Discovery in India Still Needs

Industry executives welcomed the outlay but were blunt about the bottleneck: drug regulation reforms have not kept pace with scientific ambition. Capital is only half the battle, one biotech founder said, urging single-window clearances and predictable clinical trial timelines. Venture investors who back novel medicine innovation say regulatory predictability matters more than grant size. Without drug regulation reforms, startups fear their candidates will stall in approval queues while global competitors advance. For Indian startups to compete globally, they argue, the approval clock must run as fast as the funding tap, and Indian drug startups say they will judge the scheme by how fast the first approvals move. Legal experts add that clearer intellectual property guidance for publicly funded discoveries would further encourage startups to take bold scientific bets.

From Generics to Novel Medicine Innovation

The deeper ambition is cultural: shifting Indian pharma's identity from the world's generics factory to a source of novel medicine innovation. Success would mean Indian-discovered molecules reaching global patients, and the high-value jobs and patents that come with them. Pharmaceutical research funding at this scale, experts say, could seed a pipeline that pays off a decade from now. If drug discovery in India seizes this moment, the Rs 50 crore cheques of today could look like the bargain of the century, and the country could finally claim a seat at the table where tomorrow's medicines are invented. Patient groups have also welcomed the move, noting that India-specific needs such as affordable treatments for drug-resistant tuberculosis and tropical diseases rarely attract global pharma investment.